Prasad S. Adusumilli, MD
Two novel chimeric antigen receptor (CAR) T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.
Table 1. Mesothelin-Targeted CAR T Cells in Pleural Malignancies
Table 2. HER2 CAR T Cells in Sarcomas
The participants in the study included patients with malignant pleural mesothelioma, lung cancer, and breast cancers; 40% had received ≥3 lines of prior therapy.3
... to read the full story